Company Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.
It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.
GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.
GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
| Country | United States |
| Founded | 1965 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Michael Martin Breen |
Contact Details
Address: 8000 Marina Blvd, Suite 100 Brisbane, California 94005 United States | |
| Phone | (800) 304-9888 |
| Website | gtbiopharma.com |
Stock Details
| Ticker Symbol | GTBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000109657 |
| CUSIP Number | 36254L209 |
| ISIN Number | US36254L3087 |
| Employer ID | 94-1620407 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Martin Breen | Interim Chief Executive Officer and Executive Chairman |
| Manu Ohri | Chief Financial Officer and Secretary |
| Dr. Jeffrey S. Miller M.D. | Consulting Chief Scientific Officer, Consulting Chief Medical Officer and Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | 424B3 | Prospectus |
| Jun 28, 2024 | EFFECT | Notice of Effectiveness |
| Jun 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 20, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 7, 2024 | 8-K | Current Report |
| May 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 23, 2024 | 424B5 | Filing |